1486P Nivolumab plus ipilimumab (NIVO + IPI) vs lenvatinib or sorafenib (LEN/SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): Efficacy in patients (pts) with poor prognosis and hepatic safety in the overall population from CheckMate 9DW
作者
Thomas Decaens,B. Sangro,Peter R. Galle,Shouming Qin,Leonardo Gomes da Fonseca,H. Karachiwala,Jung‐Won Park,E. Gane,Matthias Pinter,David Tai,Armando Santoro,Gonzalo Pizarro,M. Schenker,A.R. He,Nannan Hu,Martha Jimenez,Tung On Yau
PDF的下载单位、IP信息已删除
Criminology34
浮游
LPPQBB
嘻嘻哈哈
GingerF
子车茗
yang
iNk
不倦
zcl
个性的紫菜
疯狂加载ing
Smar_zcl
虎皮猫大人
HaCat
zhonglv7
zyn
liumenghan
正正
一定中课题
sissiarno
lalala
star
文静
皖公网安备34019202002308
